Objective:

To explore a non-invasive alternative to intraocular injections for delivering anti-VEGF therapy using topical eye drops.

Key Findings:

• The nanoformulated eye drops retained strong VEGF-binding and anti-angiogenic properties.
• Topical administration significantly suppressed corneal neovascular growth in animal models.
• The approach achieved effects comparable to ranibizumab without observed toxicity.

Interpretation:

The combination of a smaller antibody format with a penetration-enhancing nanocarrier may provide a viable non-invasive alternative for delivering biologics to the eye.

Limitations:

• Further studies are needed to confirm long-term safety and efficacy in larger animal models and human subjects.
• Current findings are based on laboratory and animal studies, which may not fully translate to clinical outcomes.

Conclusion:

This study presents a promising proof-of-concept for non-invasive anti-VEGF therapy via topical eye drops, potentially improving patient adherence and reducing the need for injections.